Omaveloxolone

Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO) . Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.

Product Specifications

CAS Number

[1474034-05-3]

Product Name Alternative

RTA 408

UNSPSC

12352211

Target

Apoptosis; Keap1-Nrf2; STING

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/RTA-408.html

Purity

99.52

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C(C#N)=C[C@@]2(C)[C@](CC[C@]([C@@]3(C)[C@@]4([H])[C@@]5([H])[C@@](CCC(C)(C)C5)(NC(C(F)(F)C)=O)CC3)(C)C2=CC4=O)([H])C1(C)C

Molecular Formula

C33H44F2N2O3

Molecular Weight

554.71

References & Citations

[1]Probst BL, et al. RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity. PLoS One. 2015 Apr 21;10 (4) :e0122942.|[2]Goldman DC, et al. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice. Radiat Res. 2015 Mar;183 (3) :338-44|[3]Peng Han, et al. RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene. Oxid Med Cell Longev. 24 December 2017.